Epileptic medications and improving patient outcomes
Keywords:
Epilepsy, Epileptic medications, neurological disorderAbstract
Epilepsy is a chronic neurological disorder characterized by recurrent seizures, which are sudden and uncontrolled electrical disturbances in the brain. It is one of the most common neurological conditions, affecting approximately 50 million people worldwide (World Health Organization, 2019). Effective management of epilepsy is crucial, as uncontrolled seizures can lead to significant physical, psychological, and social consequences. The treatment of epilepsy primarily involves the use of antiepileptic drugs (AEDs), also known as anticonvulsants. These medications work by modulating the electrical activity in the brain, thereby reducing the occurrence and severity of seizures. Over the past several decades, research has focused on understanding the mechanisms of action, efficacy, and safety of various AEDs, as well as the factors that influence their clinical use. This study aims to provide a comprehensive review of the research literature on epileptic medications, covering key aspects such as: 1) The pharmacological mechanisms of action of AEDs; 2) The efficacy and safety profiles of established and newer AEDs; 3) Factors influencing the selection and use of AEDs, including patient characteristics, comorbidities, and drug interactions; 4) Emerging trends and future directions in the development and utilization of epileptic medications.
Downloads
References
Brivaracetam Prescribing Information. (2022). UCB Pharma, Inc.
Keppra Prescribing Information. (2022). UCB Pharma, Inc.
Kwan, P., & Brodie, M. J. (2000). Early identification of refractory epilepsy. New England Journal of Medicine, 342(5), 314-319. DOI: https://doi.org/10.1056/NEJM200002033420503
Lacosamide Prescribing Information. (2022). UCB Pharma, Inc.
Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., Chadwick, D. W., ... & Tudur-Smith, C. (2007). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. The Lancet, 369(9566), 1000-1015. DOI: https://doi.org/10.1016/S0140-6736(07)60460-7
Perampanel Prescribing Information. (2022). Eisai Inc.
World Health Organization. (2019). Epilepsy.
Published
How to Cite
Issue
Section
Copyright (c) 2024 International journal of health sciences

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.








